Cytokinetics
Clinical trials sponsored by Cytokinetics, explained in plain language.
Biopharmaceutical company focused on muscle biology and cardiac muscle diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Heart drug aficamten tested for Long-Term safety in 900 patients
Disease control ENROLLING_BY_INVITATIONThis study follows 900 people with hypertrophic cardiomyopathy who have already taken aficamten in earlier trials. Researchers want to see if the drug is safe and tolerable over a longer period. Participants take aficamten tablets daily, with regular clinic visits to monitor for …
Phase: PHASE2, PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New heart drug aficamten aims to boost exercise and quality of life in HCM patients
Symptom relief OngoingThis phase 3 trial tests whether aficamten, an oral drug, can improve quality of life and exercise capacity in 500 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, a heart condition that makes the heart muscle thick and stiff. Participants receive either afica…
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC